Jan 23 (Reuters) - Sun Pharmaceutical Industries, India's top drugmaker by revenue, said on Friday that it has received regulatory approval to manufacture and sell generic semaglutide in India.
Advertisement
(Reporting by Kashish Tandon in Bengaluru; Editing by Sherry Jacob-Phillips)
